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Abstract
Background: Typically, DNA immunization via the intramuscular route induces specific, Th1-dominant immune responses.
However, plasmids expressing viral proteins fused to cytotoxic T lymphocyte antigen 4 (CTLA-4) primed Th2-biased
responses and were able to induced effective protection against viral challenge in the woodchuck model. Thus, we
addressed the question in the mouse model how the Th1/Th2 bias of primed immune responses by a DNA vaccine
influences hepatitis B virus (HBV) clearance.
Principal Findings: Plasmids expressing HBV core protein (HBcAg) or HBV e antigen and HBcAg fused to the extracellular
domain of CTLA-4 (pCTLA-4-HBc), CD27, and full length CD40L were constructed. Immunizations of these DNA plasmids
induced HBcAg-specific antibody and cytotoxic T-cell responses in mice, but with different characteristics regarding the
titers and subtypes of specific antibodies and intensity of T-cell responses. The plasmid pHBc expressing HBcAg induced an
IgG2a-dominant response while immunizations of pCTLA-4-HBc induced a balanced IgG1/IgG2a response. To assess the
protective values of the immune responses of different characteristics, mice were pre-immunized with pCTLA-4-HBc and
pHBc, and challenged by hydrodynamic injection (HI) of pAAV/HBV1.2. HBV surface antigen (HBsAg) and DNA in peripheral
blood and HBcAg in liver tissue were cleared with significantly accelerated kinetics in both groups. The clearance of HBsAg
was completed within 16 days in immunized mice while more than 50% of the control mice are still positive for HBsAg on
day 22. Stronger HBcAg-specific T-cell responses were primed by pHBc correlating with a more rapid decline of HBcAg
expression in liver tissue, while anti-HBs antibody response developed rapidly in the mice immunized with pCTLA-4-HBc,
indicating that the Th1/Th2 bias of vaccine-primed immune responses influences the mode of viral clearance.
Conclusion: Viral clearance could be efficiently achieved by Th1/Th2-balanced immune response, with a small but
significant shift in T-cell and B-cell immune responses.
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Introduction
Hepatitis B virus (HBV) is a major cause of acute and chronic
hepatitis in human. About 350 million people worldwide are
chronically infected with HBV and are at high risk of developing
liver cirrhosis and hepatocellular carcinoma. The persistent HBV
infection in patients is considered as a result of inadequate host
immune responses with weak or absent HBV-specific cytotoxic T
lymphocyte (CTL) response [1–3]. Patients with chronic HBV
infection do not mount effective T-cell responses to HBV core
protein (HBcAg) and envelope protein (HBsAg). In the past
decades, various immunotherapeutic strategies have been evalu-
ated in experimental models as well as in preliminary clinical trials
trying to stimulate HBV-specific immune responses. Only two
candidate vaccines are now tested in clinical trials: DNA vaccine to
HBsAg [4] and immunogenic complex consisting of HBsAg and
antibody to HBsAg (HBsAb) [5]. The available results of these
clinical trials indicated that the current versions of the candidate
vaccines still need to be improved.
One of the important questions is how the nature of specific host
immune responses influences the control of viral infection and
consequently viral clearance in HBV infection. For the develop-
ment of vaccines against viral infections, an immune response of
Th1 type is preferred since the virus-specific CTL response is
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22524regarded as the crucial determinant for viral clearance. It has been
demonstrated in the chimpanzee model that a depletion of CD8
T-cells resulted in HBV persistence [3]. Viral clearance occurred
after the recovery of CD8 T-cell responses in treated animals. In
the woodchuck model, the treatment with cyclosporine A led to
the persistence of woodchuck hepatitis virus (WHV), a genetically
related virus of HBV [6]. However, the early immunization
experiments indicated that the priming of Th2-biased immune
responses may be protective against HBV or WHV infection
[7–9]. Vaccines based on proteins may preferentially induce Th2-
biased immune responses. Immunizations with HBcAg led to
partial protection against HBV in chimpanzees [7]. More
extensive studies in woodchuck model clearly showed that WHV
nucleocapsid protein (WHcAg) was able to prime protective
responses against WHV challenge [9]. However, the nature of
HBcAg- and WHcAg-specific immune responses in chimpanzees
and woodchucks, and the course of viral clearance after challenge
were not analyzed in details at that time. Menne et al.
demonstrated that the induction of Th cellular response to one
dominant T-cell epitope in WHcAg might be critical for the
protection [8].
DNA vaccines usually induce Th1-biased immune responses,
mainly due to the activation of Toll like receptor 9 mediated
cellular responses by CpG motifs within DNA sequences [10–12].
DNA vaccines against viral infection were tested in different
animal models, including mouse and large animals [13–17]. It was
evident that DNA vaccines could induce effective immune
responses against HBV in animals including chimpanzee and
human [18–19]. In the woodchuck model, DNA vaccinations were
able to induce protective immune responses to WHV [20–23]. In a
pilot trial, 10 patients with chronic HBV infection received
immunizations of DNA vaccine expressing HBV small and middle
envelope proteins [18]. Some patients developed measurable T-
cell responses after vaccinations and one patient cleared HBV,
indicating the potential usefulness of DNA vaccines. Thus, the
currently available DNA vaccine candidates need to be further
improved for their low effectiveness.
DNA vaccines are convenient for modifications by combination
with molecular adjuvants or by fusion of viral proteins to other
selected molecules. Such modified DNA vaccines were able to
prime enhanced Th1 responses with an improved CTL branch or
Th2-biased responses with improved antibody responses. As an
example, cytotoxic T lymphocyte antigen 4 (CTLA-4), a member
of CD28 family and ligand of CD80 and CD86 on antigen
presenting cells (APC) and activated B-cells, was selected to
construct fusions to different viral proteins. The fusion to the
extracellular part of CTLA-4 led to generally improved immune
responses, but shifting toward Th2 type [22,24–25]. In the
woodchuck model, the fusion plasmid of WHcAg to the
extracellular domain of CTLA-4 primed protective immune
response in naı ¨ve woodchucks [22]. The results suggested that
the specific immune response with Th2-bias may protect host from
infection, as effective as Th1 response. However, the detailed
analysis of T-cell responses was not possible in the woodchuck
model due to the lack of appropriate tools.
Therefore, we addressed the question how the protective
effectiveness of DNA vaccines is influenced by the Th1 and Th2
bias of primed specific immune responses in the mouse model. In
the present study, we constructed different DNA vaccines by
fusion of HBcAg to woodchuck CTLA-4 (pCTLA-4-HBc), mouse
CD27 (pCD27-HBc), and mouse CD40L (pCD40L-HBc) and
compared their ability to prime specific T- and B-cell responses in
mice. To examine whether the specific immune responses of
different qualities could terminate HBV replication, mice were
pre-immunized with pCTLA-4-HBc and pHBc. Hydrodynamic
injection (HI) of mice with HBV DNA was performed to monitor
the kinetic of HBV clearance from peripheral blood and liver
tissue. The results of this study suggested that HBV clearance
could be significantly accelerated by vaccine-induced Th1- and
Th2-dominant immune responses, but with differences in the
strength and quality of T-cell and antibody responses during the
viral clearance. In addition, the specific antibody responses to
HBV antigens were markedly enhanced in mice immunized with
pCTLA-4-HBc, likely due to the intrastructural T-cell help, as
described previously [9].
Materials and Methods
Ethics statements
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals according to the regulation in the People’s
Republic of China. The protocol was approved by the official
Committee on the Ethics of Animal Experiments of Wuhan
Institute of Virology, Chinese Academy of Science (Permit
Number: 2008035). All procedures were performed under
isoflurane anesthesia, and all efforts were made to minimize
suffering.
Construction of plasmids for DNA vaccination
Two plasmids pHBc and pHBe expressing HBcAg and HBeAg,
respectively, were constructed. The HBV C region and preC/C
region were amplified by PCR using primer pairs HBcP1-P2 and
HBeP1-HBcP2, respectively (Table 1). The PCR products were
cloned into pCRII vector (Invitrogen, Karlsruhe, Germany),
sequenced to exclude nucleotide misincorporation by PCR, and
recloned into pcDNA3.1 vector (Invitrogen) by restriction with
HindIII and XhoI. The expression of HBcAg or HBeAg in pHBc
and pHBe was under the control of the cytomegalovirus
immediate-early promoter (Fig.1A).
The plasmid pCTLA-4-C encoding the fusion protein of the
extracellular domain of woodchuck CTLA-4 (wCTLA-4) and
WHcAg was described in the previous work [22] and used as PCR
template. The fragment consisting of the coding regions of the
extracellular domain of wCTLA-4 and 1-149 amino acid (aa)
residues of WHcAg was amplified with primers CTLA-4-1 and
CTLA-4-2 (Table 1) and cloned into pcDNA3.1/V5-HISTO-
POHTA vector (Invitrogen), resulting in a new vector pCTLA-4-
WHc. The plasmids pCTLA-4-WHc and pHBc were digested
with EcoRV and XhoI (Invitrogen). Subsequently, the coding region
of truncated WHcAg in pCTLA-4-WHc was replaced by the
fragment encoding HBcAg from pHBc, resulting in pCTLA-4-
HBc, which produces a fusion protein of the extracellular domains
of wCTLA-4 and HBcAg (Fig.1A).
The cDNA fragments comprising the coding regions of the
extracellular domain of mouse CD27 (mCD27) and full length
mouse CD40L (mCD40L) were amplified by reverse transcription-
PCR using primers described in Table 1. Likewise, the PCR
products were cloned into pcDNA3.1/V5-HISTOPOH TA
vector and sequenced. The fragment comprising HBcAg coding
region was cut from pHBc by EcoRV and XhoI, and inserted into
the vectors with mCD27 and mCD40L cDNA fragments. This
procedure generated the plasmids pCD27-HBc and pCD40L-HBc
(Fig. 1A).
For DNA immunizations, plasmids were prepared with the Giga
plasmid purification kit (QIAGEN, Hilden, Germany). Plasmids
were dissolved in phosphate buffered saline (PBS) in a concentra-
tion of 1 mg/ml.
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and recombinant fusion proteins in transiently
transfected cells
Baby hamster kidney (BHK) cells (provided by American Type
Culture Collection, Manassas, VA) were used for transient
transfection to express recombinant proteins. Transient transfec-
tion was performed by using Lipofectamine 2000 (Gibco BRL,
Neu-Isenburg, Germany) as described previously [22]. Four
micrograms of plasmids were incubated with 10 ml of Lipofecta-
mine 2000 in 100 ml of Opti-Mem (Gibco BRL) for 45 min and
Table 1. Primers used for cloning in the present study.
Primer Position of 59base Sequence Reference
CTLA-4-1 1 59-gaa gct tat ggc ttg tct tgg act c-39 AF130428
CTLA-4-2 483 59-gga tat cat cag aat ctg ggc atg g-39 AF130428
CD27-1 178 59-cta ggt acc atg gca tgg cc acct ccc-39 L24495
CD27-2 714 59-cta gat atc gtc cga gct gca cag ggg-39 L24495
CD40L-1 13 59-cta ggt acc atg ata gaa aca tac agc-39 X65453
CD40L-2 792 59-cta gat atc gag ttt gag taa gcc aaa-39 X65453
HBcP-1 1284 59-gat atc atg gac atc gac cct tat-39 V01460
HBcP-2 736 59-ctc gag aca ttg aga ttc ccg aga-39 V01460
HBeP-1 1371 59-gat atc atg caa ctt ttt cac ctc t-39 V01460
Reference: the Genbank accession numbers of the used reference sequences are given.
The 59 extensions were added to the primers for cloning and are indicted as italic letters.
doi:10.1371/journal.pone.0022524.t001
Figure 1. Plasmids for DNA vaccination. (A) Five plasmids were constructed on the basis of pcDNA3.1. The expression of HBcAg, HBeAg, and fusion
proteins with wCTLA-4, mCD27, and mCD40L is under the control of the immediate-early promoter of cytomegalovirus. Details of constructions of the
depicted plasmids are given in Materials and Methods. (B) IF staining of cells transiently transfected with five constructed plasmids. BHK cells were
transfectedwiththeexpressionvectors,fixed,andstainedwithamousemonoclonalHBcAb.Amockcontrolwasincludedasnegativecontrol.(C)Detection
of HBeAg and other recombinant fusion proteins in the supernatants and cell lysates of transiently transfected cells by HBeAg EIA.
doi:10.1371/journal.pone.0022524.g001
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Transfected BHK cells were maintained for 48 h at 37uC, 5%
CO2, and fixed with 50% methanol. The expressed HBcAg and
other recombinant fusion proteins were detected by indirect
immunofluorescence (IF) staining using a mouse monoclonal anti-
HBcAg antibody (DAKO, Hamburg, Germany) and FITC
labeled rabbit antisera to mouse IgG (Sigma, Munich, Germany).
HBeAg and the secreted fusion proteins expressed in the cell
culture media and cell lysates were detected by HBeAg enzyme
immunoassay (EIA) kit (Kehua, Shanghai, China).
Immunization of mice by in vivo electroporation (EP)
In vivo EP of mice was performed according to the previously
described protocol [26]. Female BALB/cJ (H-2
d) mice, 6 weeks of
age, were kept under standard-pathogen-free conditions in the
Central Animal Laboratory of Wuhan Institute of Virology,
Chinese Academy of Sciences. Mice were immunized by
intramuscular injection of 30 mg of plasmids at a concentration
of 1 mg/ml into M. tibialis anterior. Two-needle array electrodes
(BTX, San Diego, CA) were inserted into the muscle immediately
after DNA delivery for electroporation. The array was inserted
longitudinally relative to the muscle fibers with a distance of 5 mm
between the electrodes. The parameters for in vivo EP were set as
followed: 20 V/mm distance between the electrodes, 50-ms pulse
length, 3 pulses with reversal of polarity after 3 pulses, 1 pulse/
second, and were controlled by a BTX 830 square wave generator
(BTX, San Diego, CA). The immunization procedure was
repeated three times at intervals of 2 weeks. The control mice
received 30 ml of PBS instead of plasmid DNA.
Serological assay
Antibodies to HBcAg or to HBsAg (HBcAb/HBsAb) were
detected by specific enzyme linked immunosorbent assays (ELISAs).
The microtiter plates coated with HBcAg or HBsAg were provided
by the commercial diagnostic kit (Kehua, Shanghai, China). 50 mlo f
serial dilutions (1:10 to 1:163,840) of mice sera were added to the
wells and incubated for 1 h at 37uC. Bound mouse IgG1 or IgG2a
antibodies were detected with appropriate secondary antibodies
labeled with horseradish peroxidase (HRP): rat anti-mouse IgG1 (BD
Pharmingen, California, USA) at a dilution of 1:1000 or goat anti-
mouse IgG2a (Southern Biotech, Brimingham, USA) at a dilution of
1:8000. The development of color occurred at room temperature and
was read at 450 nm. The cut off value was set as 2.1 times over
negative controls. The titers of antibodies to HBcAg and HBsAg were
calculated by extrapolation of ELISA values of serially diluted
samples and corresponded to the reciprocal values of the highest
dilutions that were regarded as positive.
HBsAg was detected with serum samples at 1:10 dilution by the
commercial HBsAg EIA kit (Kehua, Shanghai, China) according to
the manufacturer’s instructions. The EIA values were read at 450 nm.
The S/CO values of HBsAg in samples were calculated accordingly.
Enzyme-Linked Immunospot (ELISpot) Assay
ELISpot assay was carried out using the mouse IFN-c precoated
ELISpot Kit (Dakewe, Shenzhen, China) according to the manufac-
turer’s instructions. Briefly, 96-well flat-bottomed microtiter plates
were preincubated with the coating antibody (anti-IFN-c monoclonal
antibody) at 4uC overnight and blocked for 2 h at 37uC. Mouse
splenocytes at the density of 2610
5 cells per well were added to wells
in triplicate with 10 mg/ml peptides (HBsAg peptide 29–38:
IPQSLDSWWTSL for H-2L
d restricted CTLs and HBcAg peptide
87-95: SYVNTNMGL for H-2K
d restricted CTLs) separately and
incubated at 37uC, 5% CO2 for 24 h. 5 mg/ml of ConA (Sigma, St.
Louis, USA) was used as positive control. Thereafter, cells were
removed. Wells were washed ten times with PBS containing 0.05%
Tween-20 (PBST) and incubated with 100 ml of biotinylated anti-
IFN-c antibody for 1 h. The plates were washed again with PBST
and incubated with 50 ml HRP-strepto-avidin solution at 37uCf o r
1 h. Spot-forming cells were counted and analyzed with an ELISpot
plate reader (BioReader 4000, Biosys, Germany). Results were
presented as spot-forming cells per 26105 cells.
HBV challenge by HI of pAAV/HBV 1.2 in mice
At day 14 after the last immunization, 10 mg of pAAV/HBV
1.2 (kindly provided by Prof. Ding-Shinn Chen)[27] in a volume of
0.9% NaCl solution equivalent to 0.1 ml/g of the mouse body
weight were injected into the tail veins of mice within 8 seconds.
Detection of serum HBV DNA by real-time PCR
For detection of serum HBV DNA, each serum sample was
pretreated with 30 units of DNase I (Roche, Mannheim,
Germany) at 37uC overnight. Total DNA was extracted and
subjected to by real-time PCR for quantification of HBV DNA.
The real time PCRs were run in a light cycler DNA Master SYBR
Green kit (Roche, Mannheim, Germany) in Roche Light cycler
V.3 and with the following cycling parameters over 40 cycles:
95uC for 20 seconds (s), 57uC for 15 s, and 72uC for 10 s. The
plasmid pAAV/HBV 1.2 was diluted and served as standard. The
specificity of the PCR products was verified by melting curve
analysis and agarose gel electrophoresis.
Detection of HBcAg in liver samples by
immunohistochemical (IHC) staining
Paraffin sections were deparaffinized, rehydrated, and incubat-
ed with 3% H2O2 at 37uC for 15 min. Antigen retrieval was
achieved using microwave repair for 30 s. The primary antibody
used to detect the expression of HBcAg was rabbit anti-human
HBcAg polyclonal antibody (Neo Markers, USA) at a dilution of
1:200. The bound primary antibodies were detected with the
Dako Envision
TM Kit (Dako, Glostrup, Denmark) according to the
manufacturer’s instructions. The slides were then counterstained
with haematoxylin before being mounted.
The expression levels of HBcAg in liver tissue were defined as
quick-score which was calculated according to the modified
method of Detre S. [28]. In brief, the proportion of cells staining
positively throughout the section was termed category A and was
assigned scores from 1 to 8 (1=0–1%; 2=2–5%; 3=6–9%;
4=10–19%; 5=20–39%; 6=40–59%; 7=60–79%; 8=80–
100%). The whole section was scanned at low power in order to
gauge the general level of intensity throughout. The average
intensity, corresponding to the presence of negative, weak,
intermediate, and strong staining, was assigned scores from 0 to
3, respectively, and termed category B. The product (A6B) was
recorded as the quick-score.
Statistical analysis
The statistical analysis was carried out using GraphPad
(GraphPad Software, San Diego, USA). Analysis of variance with
Student’s t-test was used to determine significant differences in
multiple comparisons. P,0.05 was considered as statistically
significant. Data are presented as means 6 standard deviation.
Results
Construction of DNA vaccines
Five plasmids pHBc, pHBe, pCTLA-4-HBc, pCD27-HBc, and
pCD40L-HBc were used for vaccination in this study (Fig.1A).
Th Bias and Clearance of Hepatitis B Virus
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pCTLA-4-HBc and pCD27-HBc, the coding region of HBcAg
were fused to the 39 ends of the coding sequences of the
extracellular domain of wCTLA-4 (N-terminal 161 aa residues)
and mCD27 (N-terminal 179 aa residues), respectively. For
pCD40L-HBc, the entire coding region of mCD40L of 260 aa
residues were fused to HBcAg. These fusion plasmids of CTLA-4,
CD27, and CD40L with HBcAg encode the respective N-terminal
signal peptides. The transmembrane regions of wCTLA-4 and
mCD27 were removed in the encoded fusion proteins while the
transmembrane region of mCD40L was a part of the fusion
protein. Transient transfection with all five plasmids resulted in the
expression of fusion proteins, which were stained with anti-HBcAg
antibodies in IF (Fig. 1B). However, HBeAg expression in the
culture media was identified by EIA only when cells were
transfected with pHBe, pCTLA-4-HBc, and pCD27-HBc
(Fig. 1C). HBcAg expression by pHBc was undetectable in the
supernatant of transfected cells but in the cell lysate, as HBcAg is
not secreted. CD40L-HBcAg was hardly detectable by HBeAg
EIA (Fig. 1C). Compared with other plasmids, pCD40L-HBc
expressed the fusion protein more weakly in transfected cells
(Fig. 1B). Likely, the presence of the transmembrane region leads
to the retention of CD40L-HBcAg in cells and association with
membrane. HBcAg, HBeAg and constructed fusion proteins were
also detected by western blot analysis of cell lysates using the
specific anti-HBc antibody (Fig. S1). Consistently with HBeAg
EIA, HBcAg, HBeAg, CTLA-4-HBc and CD40L-HBcAg were
detected in cell lysates. CD27-HBcAg could not be identified, as its
level in cell lysate was low. Thus, a panel of modified HBcAg with
different fusion partners was expressed by the plasmids.
Subtypes and kinetics of HBcAb IgG induced in mice by
immunizations with the plasmids expressing HBcAg,
HBeAg and fusion proteins
DNA immunizations usually lead to Th1-biased immune
responses with predominant IgG2a production [10], while fusion
proteins with the extracellular domain of CTLA-4 shifts the
immune responses to Th2 type [24]. We examined which type of
HBcAg-specific immune response was primed by the plasmids
expressing fusion proteins in mice. Mice were immunized with the
five plasmids by in vivo EP at weeks 0, 2, and 4, and tested for
Figure 2. HBcAb responses induced by DNA immunizations in mice. Titers of HBcAb subtypes induced by DNA immunizations with pHBc, pHBe,
pCTLA-4-HBc, pCD27-HBc and pCD40L-HBc were determined in ELISA and calculated. The statistic significance of the results was analyzed and indicated:
*, P,0.05; **, P,0.01. (A) IgG2a and IgG1 subtypes of HBcAb at week 4, two weeks after the second immunization. (B) The ratios of IgG2a/IgG1 were
calculated at week 4. (C) IgG2a and IgG1 subtypes of HBcAb at week 8, four weeks after the third immunization. (D) IgG2a/IgG1 ratios at week 8.
doi:10.1371/journal.pone.0022524.g002
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primed increasing HBcAb IgG2a response with the numbers of
immunizations (Fig. 2A, C). pHBc induced the highest HBcAb
IgG2a titers about 1:87500 in average at week 8, while mice
immunized with pCTLA-4-HBc developed lower titers of HBcAb
IgG2a about 1:5700 in average (Fig. 2C). Five plasmids differed
strongly in the induction of HBcAb IgG1 response in mice. Only
pCTLA-4-HBc induced a significant HBcAb IgG1 response at
week 4 after two immunizations (Fig. 2A). A further immunization
boosted HBcAb IgG1 response for all plasmids, with the highest
level at about 1:12700 in average primed by pCTLA-4-HBc
(Fig. 2C), showing again that the fusion of antigens with CTLA-4
facilitates the induction of IgG1 antibodies [22].
The ratios of IgG2a/IgG1 were calculated for each group (Fig. 2B,
D). In conclusion, pCTLA-4-HBc induced both HBcAb IgG2a and
IgG1 subtypes with an IgG2a/IgG1 ratio about 1:1, indicating a
mixed Th1/Th2 response. Other plasmids primed IgG2a-dominant
HBcAb responses with IgG2a/IgG1 ratios around 10:1. The relative
dominance of HBcAb subtype IgG2a over IgG1 suggested that
pHBc, pHBe, pCD27-HBc, and pCD40L-HBc induced Th1-
dominant immune responses.
T-cell response to HBcAg epitope in mice immunized
with plasmids expressing HBcAg, HBeAg and fusion
proteins
DNA immunization is able to induce specific T-cell responses to
antigens [10]. ELISpot assays were carried out to judge the ability
of DNA plasmids to prime specific T-cell responses to HBcAg.
Mice were sacrificed at day 10 after the third immunization.
Splenocytes were taken and stimulated with the peptide aa 87–95
of HBcAg that represents a H-2K
d restricted CTL epitope. The
number of IFN-c producing cells was detected by ELISpot assay.
Such IFN-c producing cells appearing after the stimulation with
the peptide aa 87–95 of HBcAg were proven to be CD8
+ cells (Fig.
S2), consistent with the fact that this peptide represents a CTL
epitope. DNA immunizations with all five plasmids primed specific
T-cell responses to HBcAg (Fig. 3). There were no statistically
significant differences between the mice groups immunized with
five plasmids. The fusion of HBcAg with CTLA-4, CD27, or
CD40L led to a slight but not significant reduction of specific CTL
responses to HBcAg.
Immunizations with pCTLA-4-HBc and pHBc accelerated
the viral clearance after HBV challenge by HI of pAAV/
HBV 1.2 in mice
Immunizations with pCTLA-4-HBc and pHBc induced
HBcAg-specific responses with significant difference in the Th1/
Th2 dominance. While pHBc induced a Th1-dominant immune
response in mice, immunization with pCTLA-4-HBc primed the
specific response to HBcAg shifted towards Th2. We addressed the
questions whether the immune responses primed by fusion
plasmids facilitates HBV clearance and whether the distinction
in the Th1/Th2 dominance influences the kinetic of viral
clearance. Three groups with 6 mice each received immunizations
of pHBc, pCTLA-4-HBc, or PBS as control at intervals of 2 weeks.
Two weeks after the third immunization, mice were challenged
with HI of 10 mg pAAV/HBV 1.2 and then monitored for up to
22 days after HI. The serum markers of HBV infection: HBsAg,
HBsAb, HBcAb, and serum HBV DNA concentrations were
measured. After HI challenge, HBsAg became detectable in sera
of all mice from day 1 on (Fig. 4). All mice in control group
remained HBsAg positive at day 10, 3 of 6 mice were still HBsAg
positive at day 22 (Fig. 4A). Mice immunized by pCTLA-4-HBc
and pHBc cleared HBsAg with a similar but accelerated kinetic
(Fig. 4A, B). All immunized mice except one were negative for
HBsAg at day 10 (Fig. 4A). Quantitatively, HBsAg levels in mice
immunized with pHBc and pCTLA-4-HBc were already markedly
reduced at day 7 and were below the detection limit at day 10 with
only one exception. Thus, immunized mice with both pHBc and
pCTLA-4-HBc cleared serum HBsAg significantly faster than
control mice. Consistently, HBV DNA concentrations in the sera
of control mice were detected by quantitative PCR at days 3, 5,
and 7. The average initial load in control mice was 2.3610
6
copies/ml at day 3 and declined to 6.6% of the initial load at day
7. At day 3, average HBV DNA concentrations in pHBc and
pCTLA-4-HBc immunized mice were at 38.5% and 48.9% of the
initial load of control mice, respectively, and then fell under the
detection limit with accelerated kinetics. However, the kinetics of
HBV DNA clearance from peripheral blood had no significant
differences between the groups immunized with pHBc and
pCTLA-4-HBc (p.0.05) (Fig. 4C). Afterwards, HBV DNA
concentrations in the serum samples of mice were below the
detection limit of quantitative PCR (10
3 copies/ml).
Specific antibody responses to HBV proteins in mice after
HI
Control and immunized mice developed specific antibody
responses to HBV proteins after HI. The immunizations with
pHBc and pCTLA-4-HBc induced HBcAb responses in mice
(Fig. 2). After HI challenge, HBcAb responses in immunized mice
were only slightly boosted. At day 30 post HI, the end of the follow
up, the titers of HBcAb IgG including subtypes IgG2a and IgG1
were increased and higher in immunized mice than in control
mice (Fig 5A). The ratio of HBcAb IgG2a/IgG1 decreased slightly
after the HBV challenge in immunized mice due to the increase of
Figure 3. Specific T-cell responses to HBcAg epitope induced
by DNA immunizations in mice. Mice were immunized with five
plasmids pHBc, pHBe, pCTLA-4-HBc, pCD27-HBc, and pCD40L-HBc and
sacrificed to determine specific T-cell responses to the CTL epitope
HBcAg aa 87–95 at day 10 after the third immunization. IFN-c
producing cells were detected by ELISpot assay and their numbers
were shown as spot-forming cells per 2610
5 cells.
doi:10.1371/journal.pone.0022524.g003
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HBcAb response was found in pHBc immunized mice. Control
mice developed a mixed IgG2a/IgG1 HBcAb response, which was
similar to pCTLA-4-HBc immunized mice (Fig. 5B).
All three mice groups developed HBsAb responses after HI
(Fig. 5C). Importantly, significantly stronger HBsAb IgG2a and IgG1
responses were primed in the mice immunized with pCTLA-4-HBc
than in pHBc immunized mice and control mice, respectively
(Fig. 5C). The kinetics of HBsAb IgG1 response was monitored since
IgG1 was the dominant form of HBsAb. In the mice immunized with
pCTLA-4-HBc, HBsAb IgG1 reached a significantly higher level as
early as at day 10 after HI. At the following days 20 and 30, the titers
o fH B s A bI g G1i np H B c - i mm u n i z e dmi c er a i se dr a p i d l ya n dr e a c h e d
at the similar level as in pCTLA-4-HBc immunized mice (Fig. 5E).
The results showed that the development of HBsAb response after HI
challenge was facilitated by the pre-existing immune responses to
HBcAg, particularly when a Th2 response was present or co-existed
with Th1 response.
HBV-specific CTL responses in mice after HI
The clearance of HBsAg and HBV DNA occurred rapidly in
immunized mice within three weeks. To judge the involvement of
specific T-cells,HBV-specificCTLresponses weredetected at days 1,
4, 7, 10 and 20 after HI challenge by ELISpot assay of IFN-c
producing cells. In control mice, IFN-c producing cells stimulated
with peptides HBcAg aa 87–95 and HBsAg aa 29–38 representing
CTL epitopes were hardly detectable. In both immunized mice
groups, IFN-c producing cells stimulated with HBcAg peptide were
detectable at day 1 after HI (Fig. 6A). The number of IFN-c
producing cells reached the peak in pHBc-immunized mice at day 7
after HI challenge, and was significantly higher than that in pCTLA-
4-HBc immunized mice (p=0.021) (Fig. 6A). At day 10 and 20, the
response to HBcAg peptide remained high and was comparable in
both immunized groups. In addition, the immunized mice also
developed specific responses to HBsAg peptide. The HBsAg-specific
T-cellresponsereachedthepeakatday7afterHIchallengeinpHBc-
immunized mice (Fig. 6B). Interestingly, the numbers of HBsAg-
specific T-cells in the pCTLA-4-HBc immunized mice increased
continuously up to day 20 (Fig. 6B).
Thus, there was a link between the development of HBV-
specific immune responses and viral clearance. At day 7 after HBV
challenge, a strong decline of viral parameters like serum HBsAg
titer and HBV DNA concentration occurred in the immunized
mice, coincidently with the raise of specific T-cell or antibody
responses to HBV.
Expression and clearance of HBcAg in liver of mice after
HI
To further investigate HBV clearance in mice after HI
challenge, HBcAg expression in liver tissue as a viral marker was
Figure 4. Kinetics of HBsAg and HBV DNA clearance in immunized mice after HI. Mice received three immunizations with pHBc, pCTLA-4-
HBc, and PBS as control, respectively. Two weeks after the third immunization, mice were challenged by HI of pAAV/HBV1.2. (A) The percentage of
mice with detectable serum HBsAg was determined at days 1, 4, 7, 10, 16, and 22 after HI. (B) Serum HBsAg in mice was detected by ELISA. The
relative HBsAg levels were calculated by the average of S/CO values to the average of S/CO values of control mice at day 4. The average of S/CO
values in control mice at day 4 reached the peak level of 233.8 and was set as 100%. (C) HBV DNA concentrations in mice sera were determined by
real-time PCR. The relative levels of HBV DNA were calculated by the average of HBV DNA concentrations to the average of HBV DNA concentrations
of control mice at day 3. Control mice developed the peak level of serum HBV DNA concentration at 2.3610
6 copies/ml, which was set as 100%. HBV
DNA concentrations in mice sera at other time points were under the detection limit of real-time PCR at 10
3 copies/ml.
doi:10.1371/journal.pone.0022524.g004
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group were taken for a semi-quantitative assessment of IHC
staining of liver sections including numbers of positively stained
cells per field and the relative intensity of staining (Fig. 7D).
HBcAg was detected in mouse liver at day 1 after HI regardless of
the pretreatment. The expression of HBcAg remained highly
detectable until day 10 and still detectable at low levels at day 20 in
liver of control mice (Fig. 7A). However, the pHBc-immunized
mice presented only a low or absent HBcAg expression in liver at
days 7 and 10, and apparently suppressed HBsAg expression early
(Fig. 7B). In the pCTLA-4-HBc immunized mice, HBcAg
expression in liver continued to day 10 (Fig. 7C). The immunized
mice cleared HBcAg in liver at day 20, consistently with the
clearance of HBsAg from peripheral blood. These results
suggested that the clearance of HBcAg in liver occurred early in
pHBc-immunized mice, correlating with the high T-cell responses
detected in these mice.
Discussion
In the present study, we compared 5 differently modified DNA
vaccines for their ability to induce specific B-cell and T-cell
responses to HBcAg, and the characteristics of the immune
responses including the titers and subtypes of antibodies to HBcAg
and the frequencies of specific T-cells to an HBcAg epitope. It
could be shown that all tested DNA vaccines were able to prime
Figure 5. HBcAb andHBsAb responses in miceafter HI. At day 30after HI ofpAAV/HBV1.2,thetiters of HBcAb andHBsAb IgG2a andIgG1subtypes
in mice sera were determined by ELISA. (A) IgG2a and IgG1 subtypes of HBcAb. (B) The ratios of IgG2a/IgG1 of HBcAb. (C) IgG2a and IgG1 subtypes of
HBsAb. (D) The ratios of IgG2a/IgG1 of HBsAb. (E) The kinetics of HBsAb IgG1 response in mice was monitored at days 4, 7, 10, 20, and 30 after HI.
doi:10.1371/journal.pone.0022524.g005
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of DNA vaccines resulted in fine tuning of specific immune
responses regarding the strength of T-cell and B-cell responses and
the bias to Th1 or Th2. Thus, it is possible to design DNA
vaccines based on such modifications for priming desired immune
responses with fine tuning. Further, our experiments clearly
demonstrated that Th2-biased immune response to HBcAg was
able to clear HBV from liver tissue and peripheral blood, though
with the lower CTL response but more potent B-cell responses to
HBV proteins. Thus, the priming of Th1-biaed responses is not
prerequisite for the protection against HBV challenge.
Previously, we compared CD28 and CTLA-4 in fusion with
WHcAg [22]. Both fusion plasmids of WHcAg were able to shift
the WHcAg-specific immune response towards Th2 type.
However, only pCTLA-4-WHcAg enhanced the T-cell and B-
cell responses after immunizations in mice. It is hypothesized that
CTLA-4 has a high affinity to CD80 and CD86, therefore it
mediates an efficient binding of fusion proteins with WHcAg to
dendritic cells (DC). Boyle et al. demonstrated the binding of
fusion proteins to DCs via the CTLA-4-IgG fusion construct [24].
In the present study, we selected 3 genes CTLA-4, CD27, and
CD40L to construct fusion plasmids with HBcAg. All these genes
encoded molecules which were expressed on T-cells and interact
with receptors on DCs. The vaccination of pCTLA-4-HBc
induced HBcAb IgG2a and IgG1 in a balanced manner, while
other constructs primed rather IgG2a-dominant HBcAb respons-
es. Immunizations with pCD27-HBc and pHBe led to the similar
results. In the plasmid pCD40L-HBc, the full length CD40L
sequence was used, leading to the expression of a fusion protein
with a membrane anchor. Accordingly, the fusion protein CD40L-
HBcAg was detectable in transfected cells by IF but not in HBeAg
ELISA, since this protein may be associated with the cellular
membrane and could not be processed to an exported form like
other two fusion proteins. Nevertheless, immunizations with
pCD40L-HBc induced specific B-cell and T-cell responses to
HBcAg that reached a significant level after boosts. Thus, the
fusion with CTLA-4 is apparently unique to promote the shift of
immune responses towards Th2 type. It may be interesting to
understand how these fusion antigens are differently recognized
and presented by APC.
We addressed the question whether the Th1/Th2 bias of immune
responses influences the clearance of HBV in vivo by HI of pAAV/
HBV1.2 in the mouse model. Our results clearly showed that priming
of HBcAg-specific immune responsesleadsto an accelerated clearance
of HBV from periphery and liver after HI. HBsAg was detected in
peripheral blood of mice after HI and cleared in control mice after
about 4 weeks. In both groups of immunized mice, HBsAg titers
declined significantly at day 7 and became completely undetectable at
day 16. At the same time, HBV DNA level decreased rapidly under
the detection limit. In addition, the clearance of HBcAg in liver
occurred rapidly in mice immunized with pHBc, consistent with the
highest specific T-cell activity to HBcAg epitope measured in ELISpot
assay. With a slight delay, HBcAg disappeared in the liver of mice
immunized with pCTLA-4-HBc. Thus, the clearance of HBcAg from
t h el i v e rm a yt a k ep l a c ew i t has l o w e rk i n e t i ci nt h ep r e s e n c eo faT h 1 /
Th2 balanced immune response compared with a Th1 dominant
response. However, the differences in the kinetics of HBV clearance in
periphery in both immunized mouse groups are rather minor.
The HBsAb responses and T-cell responses were strongly
facilitated in mice immunized with pHBc and pCTLA-4-HBc
after HI challenge. This finding is consistent with the proposal by
Milich et al. that an HBcAg-specific response is able to provide
assistance to HBsAg-specific responses [29]. Similarly, wood-
chucks immunized with WHcAg or DNA vaccines were able to
mount a rapid antibody response to WHV surface antigen [8,22].
HBsAb responses were dominated by IgG1 in all three mice
groups. Surprisingly, mice of pCTLA-4-HBc immunized group
developed higher levels of HBsAb IgG2a than mice of other two
groups. It is likely that a high level of Th cells was primed by
pCTLA-4-HBc, therefore facilitating the development of both
HBsAb IgG2a and IgG1 fractions. In contrast, immunizations
with pHBc facilitated the development of HBsAg-specific T-cell
responses, as shown by the ELISpot assay. Thus, the Th1/Th2
bias of immune responses established by DNA vaccinations has
significant influences on the immune responses to other viral
antigens after challenge.
DNA vaccines targeting antigens to APCs were also tested for
human immunodeficiency virus (HIV) and tumor antigens. For
example, a DNA vaccine encoding a fusion protein comprised of
HIV gag p41 and a single-chain Fv antibody (scFv) specific for the
DC-restricted antigen-uptake receptor DEC205 induced signifi-
cantly higher antibody levels and increased numbers of IFN-c–
producing CD4
+ and CD8
+ T-cells, compared with non-targeted
DNA vaccine. A single intramuscular injection of the DNA
Figure 6. Specific T-cell responses to HBcAg and HBsAg epitopes in mice after HI. The specific T-cell responses to the CTL epitope HBcAg
aa 87-95 and HBsAg aa 29-38 in mice immunized with pHBc, pCTLA-4-HBc, and PBS after HI of pAAV/HBV1.2. HBcAg (A) and HBsAg (B)-specific T-cell
responses were detected by ELISpot after HI challenge at days 1, 4, 7, 10 and 20, and are presented as spot-forming cells per 2610
5 cells.
doi:10.1371/journal.pone.0022524.g006
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protected mice from an airway challenge with a recombinant
vaccinia virus expressing the HIV gag p41 [30]. In addition,
protein vaccines targeted to DEC205 on DCs improved CD4
+ T-
cell responses and therefore provided help for DNA vaccines to
induce CD8
+ T-cell immunity [31–34]. Similar approaches were
tested for tumor vaccines using fusion of CTLA-4 or CD28 and
tumor antigens to enhance specific immunity to tumor antigens
[35–37]. In addition, targeted protein vaccines of tumor antigens
are also found to induce potent antitumor immunity [38]. The
available data suggest that targeted DNA and protein vaccines to
DCs have a great potential for future development, particularly for
therapeutic approaches of chronic viral infections and tumors.
Supporting Information
Figure S1 Detection of HBcAg, HBeAg, and other fusion
proteins by western blot. HBcAg, HBeAg, and other
recombinant fusion proteins in cell lysates of transiently transfected
cells with five constructed plasmids were detected by western blot.
Protein samples were subjected to SDS-PAGE and blotted with
the monoclonal antibody to HBcAg (clone 10E11, Santa Cruz
Biotechnology, CA). Protein bands were visualized using ECL Plus
Western blotting detection reagents (Amersham Biosciences,
Buckinghamshire, UK) according to the manufacturer’s instruc-
tions. The specific products are indicated with arrows in the blot.
The predicted molecular weights of the products are: HBcAg,
21 kd; HBeAg, 23 kd; CTLA-4-HBcAg, 39 kd; CD27-HBcAg,
42 kd; CD40L-HBcAg, 51 kd. HBeAg, CTLA-4-HBcAg, and
CD27-HBcAg were secreted proteins and did not accumulate in
cell lysates. Therefore, HBeAg and CTLA-4-HBcAg were
detected weakly while CD27-HBcAg was not detected at all. This
is consistent with the results of HBeAg EIA shown in Fig. 1C. In
contrast, HBcAg was strongly expressed and accumulated in cell
lysates. CD40L-HBcAg expression was detectable in IF, but not
reactive in HBeAg EIA. A strong expression of CD40L-HBcAg
was found in cell lysates by western blot, consistently with the fact,
that this protein possesses a transmembrane segment and therefore
could not be exported.
(TIF)
Figure S2 Verification of the specificity of the T cell
response to the HBcAg derived peptide. The HBcAg
derived peptide (aa 87–95) SYVNTNMGL was used for the
Figure 7. HBcAg expression in liver of mice after HI. Livers samples were taken from mice immunized with pHBc, pCTLA-4-HBc, and PBS after
HI of pAAV/HBV1.2, fixed with formalin, and embedded in paraffine. Sections were prepared and staining with rabbit anti-human HBcAg polyclonal
antibody. Liver tissue from three mice of each group was taken at days 1, 7, 10, and 20 after HI for examination. A set of representative samples is
shown: (A) Mock group; (B) Group of mice immunized with pHBc. (C) Group of mice immunized with pCTLA-4-HBc. Magnification: 2006. (D) Quick-
sores were calculated for each group at indicated time points and presented in the graph.
doi:10.1371/journal.pone.0022524.g007
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d restricted CD8
+ CTLs. The results were
confirmed by flow cytometry. The detection of antigen-specific
CD4 and CD8 T-cells was performed by the standard flow
cytometry analysis. Briefly, splenocytes from mice were prepared
and stimulated with the peptide for 6 hours. Cell-surface staining
was performed using BD Biosciences reagents. T-cell antibodies
used are as follows: anti-CD4 (RM4-5; eBioscience, San Diego,
CA) and anti-CD8 (53–6.7; eBioscience). For analysis of antigen-
specific T-cells, intracellular cytokine staining was performed with
anti–IFN-c (XMG1.2; eBioscience). Dead cells (7-amino-actino-
mycin D positive) were excluded from analyses. Data were
acquired on the LSR II flow cytometer (BD Biosciences) from
100,000 to 300,000 lymphocyte-gated events per sample. Analyses
were done using CellQuest Pro and FACSDiva software (BD,
Biosciences). An unrelated CMV peptide was used as negative
control.
(TIF)
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